Kangtai Biological Partners with AstraZeneca and Beijing Daxing District to Boost Vaccine Market Presence

Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a prominent biopharmaceutical company based in China, has entered into a strategic agreement with UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) and the Daxing district government of Beijing. The collaboration is focused on the vaccine sector, aiming to introduce new vaccines to the Chinese market by leveraging resources from the Daxing district. The three parties will explore mutually beneficial collaboration models to facilitate the localization and enhance market access of both companies’ innovative product pipelines within China. Financial details and further specifics of the agreement have not been disclosed.- Flcube.com